BioMarin Pharmaceutical Inc. (BMRN) Covered Calls
Biomarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Its Approved products include Naglazyme, Kuvan tablets, Aldurazyme and Firdapse.
You can sell covered calls on BioMarin Pharmaceutical Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BMRN (prices last updated Mon 4:16 PM ET):
| BioMarin Pharmaceutical Inc. (BMRN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 60.88 | -0.24 | 58.50 | 61.97 | 1.2M | 23 | 12 |
| Covered Calls For BioMarin Pharmaceutical Inc. (BMRN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 60 | 1.95 | 60.02 | 0.0% | 0.0% | |
| Apr 17 | 60 | 3.00 | 58.97 | 1.7% | 15.5% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company operates its business through one segment, the biopharmaceutical development and commercialization segment. Its company's product portfolio is comprised of five approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM. Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase indicated for patients with ucopolysaccharidosis VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs. Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase, indicated for patients with PKU, which is an inherited metabolic disease that affects patients under the age of 40 in the developed world. Aldurazyme has been approved for marketing in the U.S., EU and other countries for patients with mucopolysaccharidosis. Firdapse is a form of 3, 4-diaminopyridine for the treatment of Lambert Myasthenic Syndrome. And VIMIZIM is an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company was founded on March 21, 1997 and is headquartered in Novato, CA.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | KSS covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | OWL covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? BMO Covered Calls | BMY Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
